Pharma BD Deal Intelligence

GSK plc / HUTCHMED (China) Limited

2026 · Licensing/Option · $1.3B · Complete

HUTCHMED (China) Limited granted a subsidiary of GSK plc an exclusive development and license agreement for HMPL-A830, covering worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan. GSK pays US$110 million upfront with development, regulatory and commercial milestones taking the total to up to US$1.295 billion, plus royalties on net sales. HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate (ATTC) pairing a selective KRAS small-molecule inhibitor payload with an anti-EGFR antibody. HUTCHMED oversees global Phase 1 development, expected to begin in the second half of 2026, with GSK leading global development thereafter. Initial clinical focus is colorectal, pancreatic and lung cancer.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  GSK plc deals